Unsubstantiated claims against incretin drugs draw fiery response

August 9, 2013

The conclusions reached by the authors of a recent autopsy study stating that incretin-based drugs to treat diabetes can increase the risk of pancreatic cancer are overstated and unnecessarily alarmist, according to a Critique published in Diabetes Technology & Therapeutics (DTT), a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The Critique is available free on the DTT website at www.liebertpub.com/dia.

Important differences between the two groups of patients studied were overlooked, leading to irresponsible claims made against two effective classes of glucose-lowering drugs used by millions of people with , say Evis Harja, MD, Jonathan Lord, MD, and Jay Skyler, MD, University of Miami Miller School of Medicine (Florida). They identify specific flaws in the design and analysis of the study by Butler et al. (Diabetes 2013;62:2595–2604).

In the Critique, "An Analysis of Characteristics of Subjects Examined for Incretin Effects on Pancreatic Pathology," the authors point out the "clear and unambiguous difference between the [diabetes mellitus] DM-incretin and DM-other groups." Furthermore, "the beneficial clinical effects of the incretin drugs were ignored" and claims of potential harm were made with the intent to create controversy rather than to represent the facts.

"Incretin drugs can yield significant improvement in glucose control without causing hypoglycemia, and are associated with an improved lipid profile and either no weight gain or even weight loss, which are important outcomes for patients with diabetes," says Satish Garg, MD, Editor-in-Chief of Diabetes Technology & Therapeutics and Professor of Medicine and Pediatrics at the University of Colorado Denver. "These therapeutic agents are widely used in clinical practice. The database available to judge their effects on the pancreas is small, and claims that they are harmful are unsubstantiated. Large, ongoing studies will lead to more definitive conclusions."

These studies were made possible through tissues obtained from the Network for Pancreatic donors with Diabetes (nPOD). nPOD is a multi-national collaborative investigation funded by JDRF and is designed to further scientific understanding of the causes of type 1 diabetes. "nPOD has been organized to help investigators have access to tissue samples that are normally difficult to obtain, but may prove beneficial to studies of diabetes," said Mark Atkinson, PhD, nPOD Director and Professor of Pathology at the University of Florida. "We are proud to support, free of charge, well over 100 projects with that goal and look forward to seeing additional research that will bring clarity to this question."

Explore further: Research suggests popular diabetes drugs can cause abnormal pancreatic growth in humans

More information: Harja, E., Lord, J. and Skyler, J. An Analysis of Characteristics of Subjects Examined for Incretin Effects on Pancreatic Pathology, Diabetes Technology & Therapeutics, August 8, 2013. DOI: 10.1089/dia.2013.0177.

Related Stories

Research suggests popular diabetes drugs can cause abnormal pancreatic growth in humans

March 27, 2013
(Medical Xpress)—Individuals who had taken a type of drug commonly used to treat Type 2 diabetes showed abnormalities in the pancreas, including cell proliferation, that may be associated with an increased risk of neuroendocrine ...

How can advanced imaging studies enhance diabetes management?

May 13, 2013
New approaches to applying noninvasive imaging tests such as computed tomography (CT), magnetic resonance (MR), and positron emission tomography (PET) may play a bigger role in evaluating and managing patients with diabetes. ...

New guidelines for standardizing glucose reporting and optimizing clinical decision making in diabetes

March 1, 2013
Most adults and children with type 1 diabetes are not in optimal glycemic control, despite advances in insulin formulations and delivery systems and glucose monitoring approaches. Critical barriers to optimal glycemic control ...

Understanding pancreas size may help unlock cause of Type 1 diabetes

December 12, 2012
(Medical Xpress)—People at risk for Type 1 diabetes may have fewer insulin-producing "beta" cells than people not at risk, a finding that could help researchers shed light on what causes the disease, a new University of ...

Researchers identify pivotal immune cell in Type 1 diabetes in humans

January 12, 2012
(Medical Xpress) -- Researchers at the La Jolla Institute for Allergy & Immunology have proven – for the first time in human tissues -- the specific immune system T cells which trigger the destruction of type 1 diabetes ...

Is there a link between mood and glucose control in diabetes?

May 2, 2012
When blood sugar levels in diabetes are poorly controlled, patients tend to have more complications such as depression and other mood disturbances, including anxiety and anger, and a lower overall quality of life. A better ...

Recommended for you

Diabetes can be tracked with our Google searches

July 26, 2017
The emergence of Type 2 Diabetes could be more effectively monitored using our Google searches—helping public health officials keep track of the disease and halt its spread—according to research by the University of Warwick.

Scientists discover a new way to treat type 2 diabetes

July 21, 2017
Medication currently being used to treat obesity is also proving to have significant health benefits for patients with type 2 diabetes. A new study published today in Molecular Metabolism explains how this therapeutic benefit ...

Alzheimer's drug cuts hallmark inflammation related to metabolic syndrome by 25 percent

July 20, 2017
An existing Alzheimer's medication slashes inflammation and insulin resistance in patients with metabolic syndrome, a potential therapeutic intervention for a highly dangerous condition affecting 30 percent of adults in the ...

Diabetes or its precursor affects 100 million Americans

July 19, 2017
Almost one-third of the US population—100 million people—either has diabetes or its precursor condition, known as pre-diabetes, said a government report Tuesday.

One virus may protect against type 1 diabetes, others may increase risk

July 11, 2017
Doctors can't predict who will develop type 1 diabetes, a chronic autoimmune disease in which the immune system destroys the cells needed to control blood-sugar levels, requiring daily insulin injections and continual monitoring.

Diabetes complications are a risk factor for repeat hospitalizations, study shows

July 7, 2017
For patients with diabetes, one reason for hospitalization and unplanned hospital readmission is severe dysglycemia (uncontrolled hyperglycemia - high blood sugar, or hypoglycemia - low blood sugar), says new research published ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.